[HTML][HTML] The landscape of mRNA nanomedicine
Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and
treatment of a wide range of diseases. The recent success of the two highly efficacious …
treatment of a wide range of diseases. The recent success of the two highly efficacious …
[HTML][HTML] mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
[HTML][HTML] Drug delivery systems for RNA therapeutics
RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …
[HTML][HTML] mRNA vaccines for infectious diseases: principles, delivery and clinical translation
N Chaudhary, D Weissman… - Nature reviews Drug …, 2021 - nature.com
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …
[HTML][HTML] CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
A Mackensen, JBAG Haanen, C Koenecke, W Alsdorf… - Nature Medicine, 2023 - nature.com
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid
tumors, and could be a promising treatment target. We report dose escalation results from …
tumors, and could be a promising treatment target. We report dose escalation results from …
[HTML][HTML] BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
U Sahin, A Muik, I Vogler, E Derhovanessian, LM Kranz… - Nature, 2021 - nature.com
Abstract BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that
encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …
encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …
[HTML][HTML] Engineering circular RNA for enhanced protein production
Circular RNAs (circRNAs) are stable and prevalent RNAs in eukaryotic cells that arise from
back-splicing. Synthetic circRNAs and some endogenous circRNAs can encode proteins …
back-splicing. Synthetic circRNAs and some endogenous circRNAs can encode proteins …
[HTML][HTML] BNT162b vaccines protect rhesus macaques from SARS-CoV-2
AB Vogel, I Kanevsky, Y Che, KA Swanson, A Muik… - Nature, 2021 - nature.com
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are
sufficient to immunize large populations. Here we report the preclinical development of two …
sufficient to immunize large populations. Here we report the preclinical development of two …
The dawn of mRNA vaccines: The COVID-19 case
R Verbeke, I Lentacker, SC De Smedt… - Journal of Controlled …, 2021 - Elsevier
In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based
vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for …
vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for …
[HTML][HTML] COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
U Sahin, A Muik, E Derhovanessian, I Vogler, LM Kranz… - Nature, 2020 - nature.com
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …